Osteoporosis is a common bone disease characterized by the progressive loss of bone mass and bone density. Osteoporosis ...

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has decided it cannot approve Evenity (romosozumab), issuing a negative opinion on the drug for the treatment of severe ...

The move – which comes after an agreement by UCB to reduce the price of the drug – makes Evenity (romosozumab) the first novel therapy for the bone-wasting condition to be available to the NHS ...

Today, Benzinga's options scanner spotted 11 options trades for Amgen. This isn't normal. The overall sentiment of these ...

Prescription medicine Evenity can make bones stronger but Bristol Medical School says the drug may increase the risk of heart attacks by 30%. UCB, the pharmaceutical firm which produces the drug ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 42% bearish. Among these notable ...